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Editorial
Glucagon-Like Peptide 1 (GLP-1) is a hormone belonging to 
the family of incretins whose peripheral insulinotropic effects in 
maintaining glucose homeostasis in response to food ingestion have 
long been known [1]. GLP-1 (7-36), the most common and biologically 
active form, is a 30 amino acid peptide formed by post-translational 
cleavage of the pro-glucagon gene, it shows 50% homology to glucagon 
and it is mainly produced by enteroendocrine L-cells, which secrete it 
into the bloodstream. Although GLP-1 is blood brain barrier permeable, 
it is also synthesized in the brain and, in particular, in neurons of the 
nucleus tractus solitarius and of the intermediate reticular nucleus, 
which innervate the cerebral cortex, the hypothalamus, the amygdala, 
the hippocampal region and the paraventricular nucleus of the 
thalamus [2-5]. 
In the periphery, GLP-1 has a rather short half-life, being rapidly 
inactivated to GLP-1(9-36) amide by dipetidyl peptidase IV (DPP-IV) 
[6,7] an enzyme which is present in peripheral tissues, in body fluids 
(i.e., blood plasma and cerebrospinal fluid) and seems to localize also 
in the brain [8-10]. 
GLP-1 acts by activating a classic 7TM-G-protein coupled receptor 
named GLP-1R that, in the functional studies carried out so far, has 
been shown to stimulate adenylyl cyclase via the α subunit of the Gs 
protein, thus increasing intracellular cAMP levels and triggering a 
cascade of downstream events, such as activation of PKA, Epac2, 
PKC, MAPK and PI-3K pathways. However, it has been reported that 
GLP-1R can also couple to other G-protein α-subunits (i.e., Gq, o, i), 
although the functional meaning of this molecular promiscuity is not 
fully understood [11]. 
A milestone in the understanding of the physiological roles of the 
GLP-1/GLP-1R system was the isolation and characterization of the 
DPP-IV resistant, BBB permeable GLP-1R selective agonist exendin-4 
and the selective antagonist exendin-(9-39) that permitted, in addition 
to in vitro experiments, to initiate various in vivo studies [12,13]. After 
exendin-4, liraglutide and lixisenatide have been produced as other 
GLP-1R agonists, whereas sitagliptin, saxagliptin and vidagliptin 
have been developed as selective DPP-IV inhibitors able to increase 
endogenous GLP-1 levels.
Although the interest for the GLP-1/GLP-1R system began in the 
field of diabetes treatment, it was soon clear that this hormone could 
also have important functions in the central nervous system.
The first evidence for a central physiological role of GLP-1, dates 
back to 1996 when it was shown that its intracerebroventricular (icv) 
administration, potently inhibited feeding in rats [14]. However, it was 
only six years later that the neuroprotective role GLP-1 and exendin-4 
was demonstrated for the first time [15]. In that study, activation of 
GLP-1Rs was able to completely protect cultured rat hippocampal 
neurons from apoptotic death caused by glutamate excitotoxicity 
and to greatly reduce the in vivo ibotenic acid-induced depletion of 
choline acetyltransferase in the basal forebrain, leading the authors 
to hypothesise that “….such peptides may have potential for halting 
or reversing neurodegenerative processes in CNS disorders, such as 
Alzheimer’s disease…”
Since then, a large body of evidence has accumulated indicating 
that the activation of GLP-1Rs could represent a novel and 
effective disease modifying therapeutic strategy for treating 
neurodegenerative disorders.
Indeed, both in vitro and in vivo studies using validated animal 
models of Alzheimer’s (AD) and Parkinson’s (PD) diseases, 
Huntington’s chorea, amyotrophic lateral sclerosis and stroke have 
undoubtedly demonstrated the protective properties of GLP-1R agonists 
using both anatomo-pathological and behavioural analysis [16-18].
Significant neuroprotection has been reported also for the DPP-4 
inhibitors sitagliptin and saxagliptin in PD and AD animal models, as 
well as in models of cerebral ischemia [19-21]. However, administration 
of sitagliptin to type 2 diabetic rats has been found to aggravate γ-tau 
phosphorylation in the hippocampus, thus highlighting the need of 
further studies before considering its use in AD [22].
As for the possible mechanisms through which GLP-1Rs trigger 
neuroprotection, several studies have revealed that these receptors 
are capable of stimulating neurite outgrowth, promoting adult 
neurogenesis with cell proliferation and survival, interrupting pro-
apoptotic processes, and reducing neuroinflammation. In addition, 
they have beneficial effects for mitochondrial functions by means of 
different molecular mechanisms, including the stabilisation of the 
outer membrane through activation of the PI3K/AKT pathway, thus 
preventing the initiation of the apoptotic intrinsic pathway [17,18]. 
Indeed, mitochondria dysfunctions represent a common feature of 
different neurodegenerative disorders.
It is also worth noting that GLP-1 and GLP-1R have important 
effects also on learning and memory formation both under physiological 
and pathological conditions. In fact, in rodents, icv administration 
of GLP-1 or GLP-1R overexpression resulted in the enhancement of 
learning and memory, whereas GLP-1R knock-out caused significant 
deficits in cognitive processes [23,24]. The pro-amnesic effects of 
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GLP-1R agonists are associated with the facilitation of hippocampal 
long term potentiation (LTP), the electrophysiological substrate of 
memory, as measured both in vitro and in vivo [25,26]. Accordingly, 
this synaptic plasticity phenomenon is impaired in GLP-1R knock-
out mice [24]. Moreover, administration of GLP-1, GLP-1 agonists or 
DPP-IV inhibitors rescues LTP and the memory impairment caused by 
exogenous or endogenous β-amyloid, the self-aggregating peptide that 
accumulates AD brains [21,25-30].
Such overwhelming evidence has led to clinical trials in which 
GLP-1 mimetic have been tested for their efficacy in neurodegenerative 
disorders such as PD and AD.
In the first case, a single-blind proof of concept evaluated the 
progression of motor and nonmotor symptoms in a small group 
of PD patients treated with exenatide (exendin-4) administered 
subcutaneously for 12 months and found clinically relevant 
ameliorations both in motor and cognitive performances, evaluated 
by MDS-UPDRS (Movement Disorder Society Unified Parkinson’s 
Disease Rating Scale) and Mattis DRS-2 (Dementia Rating Scale 2) at 
the end of the therapy and after two months of washout [31]. Most 
interestingly, the improvement persisted 12 months after the trial, with 
exanetide-treated patients showing a 5.6 and 5.3 point advantage on 
the MDS-UPDRS part 3 and on the Mattis DRS-2, respectively [32]. 
These encouraging results have fuelled a larger, randomized, double-
blind, placebo-controlled phase II trial that is investigating the efficacy 
of a once weekly treatment with exenatide for 48 weeks in patients with 
moderate PD (NCT01971242).
As for AD, the efficacy of a six-month treatment with liraglutide 
has been evaluated in a small, randomized, double-blind, placebo-
controlled trial on a total of 38 patients (18 liraglutide treated vs 20 
placebo) [33]. The primary outcome was the change of brain β-amyloid 
deposit assessed by PIB (Pittsburgh compound B) PET scan, whereas 
secondary outcomes were changes in CMRglc (Cerebral Metabolic Rate 
of glucose consumption) measured by FDG (Fluoro Deoxy Glucose) 
PET scan and changes in cognition assessed by the WMS-IV (Wechsler 
Memory Scale IV). The results show that CMRglc significantly declined 
in placebo controls but not in liraglutide-treated patients. Actually, the 
values were increased in this group, although insignificantly. However, 
β-amyloid load and cognitive scores were not different between the two 
groups. At the moment, there are two ongoing randomized, double 
blind, phase II trials: a pilot study that will evaluate safety, tolerability 
and efficacy of exenatide on MCI (Mild Cognitive Impairment) and 
early AD (NCT01255163) with an estimated enrolment of 100 patients, 
and a safety/efficacy study of liraglutide on mild AD with an estimated 
enrolment of 206 patients (NCT01843075).
In conclusion, pre-clinical and clinical studies point to stimulation 
of GLP-1 receptors as a novel and promising neuroprotective 
pharmacological intervention to treat different neurodegenerative 
disorders with the hope of slowing their progression. Will these 
promises become reality?
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